Vicore Pharma: Interim Report April-June 2023
Stockholm, August 24, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the second quarter 2023. Important events during the second quarter In May, Vicore reported new interim 36-week data from the phase […]